BioCentury | Feb 19, 2021
Deals

Rigel’s decision tree behind its RIPK1 Lilly deal

...pipelines, of which one other is part of a pharma-biotech partnership. Sanofi (Euronext:SAN; NASDAQ:SNY) and Denali Therapeutics Inc....
BioCentury | Feb 19, 2021
Translation in Brief

mAb reduces amyloid plaques without hemorrhage; plus Dyno and Ally’s AAV technologies and more

...Staff Writer Alzheimer’s disease immunotherapy reduces β-amyloid without increasing brain bleedingPublished in Science Translational Medicine, Denali Therapeutics Inc....
...Compound #), PLX4032 (Compound #), vemurafenib (Generic) Victrelis, boceprevir (MK-3034, sch 503034) Incivek, Incivo, Telavic, telaprevir (MP-424, VX-950) Denali Therapeutics Inc. Washington...
BioCentury | Feb 13, 2021
Product Development

Howdy partner: MD Anderson’s evolving industry collaboration strategy

...a Neurodegeneration Consortium (NDC), a partnership with three other academic institutions that formed a collaboration with Denali Therapeutics Inc....
BioCentury | Feb 13, 2021
Product Development

Feb. 12 Quick Takes: G1’s first approval is first in class; plus Seagen, Denali, Roche and Takeda

...I/II study of ETV:IDS (DNL310) added to the early evidence that transport vehicle technology from Denali Therapeutics Inc....
BioCentury | Jan 30, 2021
Product Development

ALS looks up as clinical pipeline explodes

...risk alleles for ALS in RNA binding proteins. Denali Therapeutics Inc....
...T cells. Selina Koch Biogen Inc. Ionis Pharmaceuticals Inc. Novartis AG Prilenia Therapeutics Denali Therapeutics Orphazyme Amylyx...
BioCentury | Jan 28, 2021
Finance

$1.9B fund gives Arch flexibility for more megarounds

...progress.In recent years, Arch Venture Partners has participated in nine-digit rounds for several biotechs, including neurodegeneration company Denali Therapeutics Inc....
BioCentury | Dec 17, 2020
Emerging Company Profile

Vigil: restoring the vigilance of microglia

...for neuroscience indications: Alector Inc. (NASDAQ:ALEC), with AL002 in Phase I testing for Alzheimer’s disease, and Denali Therapeutics Inc....
...expressed on myeloid cells 2 (TREM2) Danielle Golovin AL002 DNL919 (ATV:TREM2) Atlas Venture Amgen Inc. Northpond Ventures Hatteras Venture Partners Alexandria Venture Investments Alector Inc. Denali Therapeutics Inc. Triggering...
BioCentury | Dec 16, 2020
Emerging Company Profile

With crossover funding already in place, Stagliano’s Neuron23 exits stealth with programs in neurology, systemic immune disease

...targeting LRRK2 from Biogen Inc. (NASDAQ:BIIB) and Denali Therapeutics Inc....
BioCentury | Nov 14, 2020
Product Development

Denali holds gains after first human proof of concept for brain delivery tech

...ALS), Parkinson’s and Alzheimer’s.TARGETSIDS —Iduronate 2-sulfatase Selina Koch DNL310 (ETV:IDS) Denali Therapeutics Endocrine/Metabolic Mucopolysaccharidosis Hunter...
BioCentury | Sep 11, 2020
Deals

Data Bytes: upfront tally shows 2020’s dealmakers playing catch-up

...Deal ”; “AZ Goes Early for its Latest $1B ADC Deal”). Amanda Micklus Biogen Inc. Daiichi Sankyo Co. Ltd. Denali Therapeutics Inc. AstraZeneca...
Items per page:
1 - 10 of 96
BioCentury | Feb 19, 2021
Deals

Rigel’s decision tree behind its RIPK1 Lilly deal

...pipelines, of which one other is part of a pharma-biotech partnership. Sanofi (Euronext:SAN; NASDAQ:SNY) and Denali Therapeutics Inc....
BioCentury | Feb 19, 2021
Translation in Brief

mAb reduces amyloid plaques without hemorrhage; plus Dyno and Ally’s AAV technologies and more

...Staff Writer Alzheimer’s disease immunotherapy reduces β-amyloid without increasing brain bleedingPublished in Science Translational Medicine, Denali Therapeutics Inc....
...Compound #), PLX4032 (Compound #), vemurafenib (Generic) Victrelis, boceprevir (MK-3034, sch 503034) Incivek, Incivo, Telavic, telaprevir (MP-424, VX-950) Denali Therapeutics Inc. Washington...
BioCentury | Feb 13, 2021
Product Development

Howdy partner: MD Anderson’s evolving industry collaboration strategy

...a Neurodegeneration Consortium (NDC), a partnership with three other academic institutions that formed a collaboration with Denali Therapeutics Inc....
BioCentury | Feb 13, 2021
Product Development

Feb. 12 Quick Takes: G1’s first approval is first in class; plus Seagen, Denali, Roche and Takeda

...I/II study of ETV:IDS (DNL310) added to the early evidence that transport vehicle technology from Denali Therapeutics Inc....
BioCentury | Jan 30, 2021
Product Development

ALS looks up as clinical pipeline explodes

...risk alleles for ALS in RNA binding proteins. Denali Therapeutics Inc....
...T cells. Selina Koch Biogen Inc. Ionis Pharmaceuticals Inc. Novartis AG Prilenia Therapeutics Denali Therapeutics Orphazyme Amylyx...
BioCentury | Jan 28, 2021
Finance

$1.9B fund gives Arch flexibility for more megarounds

...progress.In recent years, Arch Venture Partners has participated in nine-digit rounds for several biotechs, including neurodegeneration company Denali Therapeutics Inc....
BioCentury | Dec 17, 2020
Emerging Company Profile

Vigil: restoring the vigilance of microglia

...for neuroscience indications: Alector Inc. (NASDAQ:ALEC), with AL002 in Phase I testing for Alzheimer’s disease, and Denali Therapeutics Inc....
...expressed on myeloid cells 2 (TREM2) Danielle Golovin AL002 DNL919 (ATV:TREM2) Atlas Venture Amgen Inc. Northpond Ventures Hatteras Venture Partners Alexandria Venture Investments Alector Inc. Denali Therapeutics Inc. Triggering...
BioCentury | Dec 16, 2020
Emerging Company Profile

With crossover funding already in place, Stagliano’s Neuron23 exits stealth with programs in neurology, systemic immune disease

...targeting LRRK2 from Biogen Inc. (NASDAQ:BIIB) and Denali Therapeutics Inc....
BioCentury | Nov 14, 2020
Product Development

Denali holds gains after first human proof of concept for brain delivery tech

...ALS), Parkinson’s and Alzheimer’s.TARGETSIDS —Iduronate 2-sulfatase Selina Koch DNL310 (ETV:IDS) Denali Therapeutics Endocrine/Metabolic Mucopolysaccharidosis Hunter...
BioCentury | Sep 11, 2020
Deals

Data Bytes: upfront tally shows 2020’s dealmakers playing catch-up

...Deal ”; “AZ Goes Early for its Latest $1B ADC Deal”). Amanda Micklus Biogen Inc. Daiichi Sankyo Co. Ltd. Denali Therapeutics Inc. AstraZeneca...
Items per page:
1 - 10 of 96